TREATMENT OF MINIMAL CHANGE DISEASE IN ADULTS: CURRENT PRACTICE AND FUTURE DIRECTIONS – A NARRATIVE LITERATURE REVIEW
Abstract
Research Objectives: This review aims to summarize the current therapeutic strategies for adults with MCD and to discuss future treatment directions in light of emerging immunological and molecular findings.
Methods: Literature was searched using PubMed and Google Scholar, with a focus on studies from the past five years. Keywords used in the search included: „minimal change disease”, „nephrotic syndrome”, „glucocorticoids”, „rituximab”, „TRPC6”, and „adults”.
Key Findings: Minimal change disease (MCD) is the most common cause of nephrotic syndrome in children and a significant contributor in adults. Although its clinical course in adults is often mild and steroid-responsive, many patients experience relapses, steroid resistance, or develop adverse effects related to prolonged glucocorticoid use.
Glucocorticoids remain the first-line therapy for MCD, achieving remission in approximately 90% of adults, but relapses affect more than half of these patients. Alternative immunosuppressive therapies have shown comparable efficacy in inducing remission and may lower the relapse rate. Rituximab has shown significant therapeutic efficacy in steroid-dependent and frequently relapsing cases. Several new pharmacological agents - including TRPC6 inhibitors and ManNAc - are under investigation. Immunomodulatory therapies targeting B and T cells also show promise and are being explored in early-phase studies.
Conclusions: MCD presents ongoing therapeutic challenges due to steroid-related toxicity, and heterogeneous treatment responses. A deeper understanding of the disease’s immunopathogenesis is opening new avenues for targeted and safer therapies. Further studies are needed to optimize treatment protocols and improve long-term prognosis and quality of life.
References
Allison, A. C., & Eugui, E. M. (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47(2–3), 85–118. https://doi.org/10.1016/s0162-3109(00)00188-0
Aslam, A., & Koirala, A. (2023). Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis. Glomerular Diseases, 3(1), 211–219. https://doi.org/10.1159/000533695
Cade, R., Mars, D., Privette, M., Thompson, R., Croker, B., Peterson, J., & Campbell, K. (1986). Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Archives of Internal Medicine, 146(4), 737–741.
Campbell, R. E., & Thurman, J. M. (2022). The Immune System and Idiopathic Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology : CJASN, 17(12), 1823–1834. https://doi.org/10.2215/CJN.07180622
Chang, J. H., Kim, D. K., Kim, H. W., Park, S. Y., Yoo, T.-H., Kim, B. S., Kang, S.-W., Choi, K. H., Han, D.-S., Jeong, H. J., & Lee, H. Y. (2009). Changing prevalence of glomerular diseases in Korean adults: A review of 20 years of experience. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 24(8), 2406–2410. https://doi.org/10.1093/ndt/gfp091
Chapter 5: Minimal-change disease in adults. (2012). Kidney International Supplements, 2(2), 177–180. https://doi.org/10.1038/kisup.2012.18
Chen, R., Lin, Q., Tang, H., Dai, X., Jiang, L., Cui, N., & Li, X. (2024). PD-1 immunology in the kidneys: A growing relationship. Frontiers in Immunology, 15, 1458209. https://doi.org/10.3389/fimmu.2024.1458209
Chen, S., Huang, Y., & Qu, Z. (2025). Telitacicept monotherapy for refractory idiopathic membranous nephropathy: A case report and literature review. Frontiers in Medicine, 12, 1571616. https://doi.org/10.3389/fmed.2025.1571616
Chin, H. J., Chae, D.-W., Kim, Y. C., An, W. S., Ihm, C., Jin, D.-C., Kim, S. G., Kim, Y.-L., Kim, Y.-S., Kim, Y.-G., Koo, H. S., Lee, J. E., Lee, K. W., Oh, J., Park, J. H., Jiang, H., Lee, H., & Lee, S. K. (2021). Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults. Journal of the American Society of Nephrology : JASN, 32(1), 199–210. https://doi.org/10.1681/ASN.2019050546
Chugh, S. S., & Clement, L. C. (2023). “Idiopathic” minimal change nephrotic syndrome: A podocyte mystery nears the end. American Journal of Physiology - Renal Physiology, 325(6), F685–F694. https://doi.org/10.1152/ajprenal.00219.2023
Chugh, S. S., Clement, L. C., & Macé, C. (2012). New Insights Into Human Minimal Change Disease: Lessons From Animal Models. American Journal of Kidney Diseases, 59(2), 284–292. https://doi.org/10.1053/j.ajkd.2011.07.024
Colattur, S. N., & Korbet, S. M. (2000). Long-term Outcome of Adult Onset Idiopathic Minimal Change Disease. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 11(3), 334–344.
Coppo, R., Camilla, R., Porcellini, M. G., Peruzzi, L., Gianoglio, B., Amore, A., Daprà, V., Loiacono, E., Fonsato, V., Dal Canton, A., Esposito, C., Esposito, P., & Tovo, P. A. (2012). Saquinavir in steroid-dependent and -resistant nephrotic syndrome: A pilot study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 27(5), 1902–1910. https://doi.org/10.1093/ndt/gfs035
Dossier, C., Bonneric, S., Baudouin, V., Kwon, T., Prim, B., Cambier, A., Couderc, A., Moreau, C., Deschenes, G., & Hogan, J. (2023). Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology : CJASN, 18(12), 1555–1562. https://doi.org/10.2215/CJN.0000000000000288
Fenton, A., Smith, S. W., & Hewins, P. (2018). Adult minimal-change disease: Observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC Nephrology, 19, 207. https://doi.org/10.1186/s12882-018-0999-x
Floege, J., Gibson, K. L., Vivarelli, M., Liew, A., Radhakrishnan, J., & Rovin, B. H. (2025). KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney International, 107(5), S241–S289. https://doi.org/10.1016/j.kint.2024.11.007
Gauckler, P., Shin, J. I., Alberici, F., Audard, V., Bruchfeld, A., Busch, M., Cheung, C. K., Crnogorac, M., Delbarba, E., Eller, K., Faguer, S., Galesic, K., Griffin, S., Hrušková, Z., Jeyabalan, A., Karras, A., King, C., Kohli, H. S., Maas, R., … Kronbichler, A. (2020). Rituximab in adult minimal change disease and focal segmental glomerulosclerosis—What is known and what is still unknown? Autoimmunity Reviews, 19(11), 102671. https://doi.org/10.1016/j.autrev.2020.102671
Goodwin, J. E. (2019). Role of the glucocorticoid receptor in glomerular disease. American Journal of Physiology - Renal Physiology, 317(1), F133–F136. https://doi.org/10.1152/ajprenal.00217.2019
Hackl, A., Nüsken, E., Voggel, J., Abo Zed, S. E. D., Binz-Lotter, J., Unnersjö-Jess, D., Müller, C., Fink, G., Bohl, K., Wiesner, E., Diefenhardt, P., Dafinger, C., Chen, H., Wohlfarth, M., Müller, R.-U., Hackl, M. J., Schermer, B., Nüsken, K.-D., & Weber, L. T. (2023). The effect of mycophenolate mofetil on podocytes in nephrotoxic serum nephritis. Scientific Reports, 13(1), 14167. https://doi.org/10.1038/s41598-023-41222-1
Hansrivijit, P., Cheungpasitporn, W., Thongprayoon, C., & Ghahramani, N. (2020). Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: A systematic review and meta-analysis. BMC Nephrology, 21, 134. https://doi.org/10.1186/s12882-020-01797-7
Hansrivijit, P., Puthenpura, M. M., & Ghahramani, N. (2020). Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies. Clinical Nephrology, 94(3), 117–126. https://doi.org/10.5414/CN110134
Hodgens, A., & Sharman, T. (2025). Corticosteroids. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK554612/
Hou, W., Liu, B., & Xu, H. (2019). Triptolide: Medicinal chemistry, chemical biology and clinical progress. European Journal of Medicinal Chemistry, 176, 378–392. https://doi.org/10.1016/j.ejmech.2019.05.032
Huang, J. J., Hsu, S. C., Chen, F. F., Sung, J. M., Tseng, C. C., & Wang, M. C. (2001). Adult-onset minimal change disease among Taiwanese: Clinical features, therapeutic response, and prognosis. American Journal of Nephrology, 21(1), 28–34. https://doi.org/10.1159/000046215
Kechagias, K. S., Laleye, J. D., Drmota, J., Geropoulos, G., Kyrtsonis, G., Zafeiri, M., Triantafyllidis, K. K., & Stathi, D. (2024). Minimal change disease following COVID-19 vaccination: A systematic review. PLOS ONE, 19(3), e0297568. https://doi.org/10.1371/journal.pone.0297568
Khalil, R., Koop, K., Kreutz, R., Spaink, H. P., Hogendoorn, P. C., Bruijn, J. A., & Baelde, H. J. (2019). Increased dynamin expression precedes proteinuria in glomerular disease. The Journal of Pathology, 247(2), 177–185. https://doi.org/10.1002/path.5181
Koirala, A., & Jefferson, J. A. (2021). Steroid Minimization in Adults with Minimal Change Disease. Glomerular Diseases, 1(4), 237–249. https://doi.org/10.1159/000517626
Lan, L., Lin, Y., Yu, B., Wang, Y., Pan, H., Wang, H., Lou, X., Lang, X., Zhang, Q., Jin, L., Yang, Y., Xiao, L., Chen, J., & Han, F. (2024). Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study. American Journal of Nephrology, 55(1), 25–36. https://doi.org/10.1159/000535010
Li, H., Shi, X., Shen, H., Li, X., Wang, H., Li, H., Xu, G., & Chen, J. (2012). Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: A multicenter, open-label, nonrandomized cohort trial. Clinical Therapeutics, 34(5), 1112–1120. https://doi.org/10.1016/j.clinthera.2012.03.008
Li, S., Ding, L., Yang, Y., & Yang, X. (2023). Telitacicept for minimal change disease. The Kaohsiung Journal of Medical Sciences, 39(7), 748–749. https://doi.org/10.1002/kjm2.12719
Li, X., Liu, Z., Wang, L., Wang, R., Ding, G., Shi, W., Fu, P., He, Y., Cheng, G., Wu, S., Chen, B., Du, J., Ye, Z., Tao, Y., Huo, B., Li, H., & Chen, J. (2017). Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome. Journal of the American Society of Nephrology : JASN, 28(4), 1286–1295. https://doi.org/10.1681/ASN.2016030342
Lin, D.-W., Chang, C.-C., Hsu, Y.-C., & Lin, C.-L. (2022). New Insights into the Treatment of Glomerular Diseases: When Mechanisms Become Vivid. International Journal of Molecular Sciences, 23(7), 3525. https://doi.org/10.3390/ijms23073525
Lionaki, S., Mantios, E., Tsoumbou, I., Marinaki, S., Makris, G., Liapis, G., Vergandis, C., & Boletis, I. (2021). Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease. Journal of Clinical Medicine, 10(16), 3632. https://doi.org/10.3390/jcm10163632
Liu, F., Chen, J., Luo, C., & Meng, X. (2022). Pathogenic Role of MicroRNA Dysregulation in Podocytopathies. Frontiers in Physiology, 13, 948094. https://doi.org/10.3389/fphys.2022.948094
Liu, L., Qin, Y., Cai, J., Wang, H., Tao, J., Li, H., Chen, L., Li, M., Li, X., & Li, X. (2011). Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clinical Immunology, 139(3), 314–320. https://doi.org/10.1016/j.clim.2011.02.018
Lu, J., Xu, Z., Xu, W., Gong, L., Xu, M., Tang, W., Jiang, W., Xie, F., Ding, L., & Qian, X. (2022). Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: A meta-analysis. International Urology and Nephrology, 54(9), 2205–2213. https://doi.org/10.1007/s11255-022-03122-7
Ma, J., Ren, L., Su, Q., Lv, X., Sun, M., Wei, Y., Dai, L., & Bian, X. (n.d.). TRPC6 knockdown-mediated ERK1/2 inactivation alleviates podocyte injury in minimal change disease via upregulating Lon peptidase 1. Renal Failure, 46(2), 2431150. https://doi.org/10.1080/0886022X.2024.2431150
Mbakop, C., DeVita, M. V., Wahl, S. J., Bijol, V., & Rosenstock, J. L. (2021). Adult primary nephrotic syndrome trends by race: A diminished frequency of focal segmental glomerulosclerosis in non-black patients. International Urology and Nephrology, 53(4), 719–724. https://doi.org/10.1007/s11255-020-02658-w
McCaffrey, J. C., Webb, N. J., Poolman, T. M., Fresquet, M., Moxey, C., Zeef, L. A. H., Donaldson, I. J., Ray, D. W., & Lennon, R. (2017). Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1. Scientific Reports, 7, 6725. https://doi.org/10.1038/s41598-017-06810-y
Medjeral-Thomas, N. R., Lawrence, C., Condon, M., Sood, B., Warwicker, P., Brown, H., Pattison, J., Bhandari, S., Barratt, J., Turner, N., Cook, H. T., Levy, J. B., Lightstone, L., Pusey, C., Galliford, J., Cairns, T. D., & Griffith, M. (2020). Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease. Clinical Journal of the American Society of Nephrology : CJASN, 15(2), 209–218. https://doi.org/10.2215/CJN.06180519
Minimal Change Disease—DynaMed. (n.d.). Retrieved July 12, 2025, from https://www.dynamed.com/condition/minimal-change-disease#GUID-7696237B-A946-4335-B43E-095830792AEB
Mohammadi, O., & Kassim, T. A. (2025). Azathioprine. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK542190/
Müller-Deile, J., Teng, B., Schenk, H., Haller, H., Reiser, J., Sever, S., & Schiffer, M. (2016). Drugs targeting dynamin can restore cytoskeleton and focal contact alterations of urinary podocytes derived from patients with nephrotic syndrome. Annals of Translational Medicine, 4(21), 439. https://doi.org/10.21037/atm.2016.10.72
Nakagawa, N., Kimura, T., Sakate, R., Wada, T., Furuichi, K., Okada, H., Isaka, Y., & Narita, I. (2023). Demographics and treatment of patients with primary nephrotic syndrome in Japan using a national registry of clinical personal records. Scientific Reports, 13, 14771. https://doi.org/10.1038/s41598-023-41909-5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2023). A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases (Clinical Trial Registration No. NCT02639260). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT02639260
Ogino, M. H., & Tadi, P. (2025). Cyclophosphamide. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK553087/
Patil, M. R., Divyaveer, S., Raychaudhary, A., Trivedi, M., Mahajan, C., Sarkar, D., & Pandey, R. (2019). Tacrolimus as the First-Line Agent in Adult-Onset Minimal Change Disease: A Randomized Controlled Study. Saudi Journal of Kidney Diseases and Transplantation, 30(1), 129–137. https://doi.org/10.4103/1319-2442.252902
Pippin, J. W., Kaverina, N., Wang, Y., Eng, D. G., Zeng, Y., Tran, U., Loretz, C. J., Chang, A., Akilesh, S., Poudel, C., Perry, H. S., O’Connor, C., Vaughan, J. C., Bitzer, M., Wessely, O., & Shankland, S. J. (n.d.). Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease. The Journal of Clinical Investigation, 132(16), e156250. https://doi.org/10.1172/JCI156250
Ponticelli, C., Edefonti, A., Ghio, L., Rizzoni, G., Rinaldi, S., Gusmano, R., Lama, G., Zacchello, G., Confalonieri, R., & Altieri, P. (1993). Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: A multicentre randomized controlled trial. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 8(12), 1326–1332.
Ponticelli, C., & Locatelli, F. (2018). Glucocorticoids in the Treatment of Glomerular Diseases. Clinical Journal of the American Society of Nephrology : CJASN, 13(5), 815–822. https://doi.org/10.2215/CJN.12991117
Prasad, N., Manjunath, R., Rangaswamy, D., Jaiswal, A., Agarwal, V., Bhadauria, D., Kaul, A., Sharma, R., & Gupta, A. (2018). Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study. Indian Journal of Nephrology, 28(1), 46–52. https://doi.org/10.4103/ijn.IJN_240_16
Ransom, R. F., Lam, N. G., Hallett, M. A., Atkinson, S. J., & Smoyer, W. E. (2005). Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney International, 68(6), 2473–2483. https://doi.org/10.1111/j.1523-1755.2005.00723.x
Rathore, S. S., Nirja, K., & Choudhary, S. (n.d.). Efficacy of Mycophenolate in Steroid-Dependent and Frequently Relapsing Adult Minimal Change Disease: A Retrospective Cohort Study. Cureus, 17(1), e77314. https://doi.org/10.7759/cureus.77314
Ren, H., Shen, P., Li, X., Pan, X., Zhang, W., & Chen, N. (2013). Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: A randomized controlled trial. American Journal of Nephrology, 37(1), 84–90. https://doi.org/10.1159/000346256
Roman, M., & Nowicki, M. (2024). Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility. International Journal of Molecular Sciences, 25(22), 12174. https://doi.org/10.3390/ijms252212174
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., Jayne, D. R. W., Jha, V., Liew, A., Liu, Z.-H., Mejía-Vilet, J. M., Nester, C. M., Radhakrishnan, J., Rave, E. M., Reich, H. N., … Floege, J. (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100(4), S1–S276. https://doi.org/10.1016/j.kint.2021.05.021
Salcido-Ochoa, F., Hue, S. S.-S., Haase, D., Choo, J. C. J., Yusof, N., Li, R. L., Allen, J. C., Iqbal, J., Loh, A. H. L., & Rotzschke, O. (2017). Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study. International Journal of Nephrology, 2017, 3095425. https://doi.org/10.1155/2017/3095425
Saqib, U., Munjuluri, S., Sarkar, S., Biswas, S., Mukherjee, O., Satsangi, H., Baig, M. S., Obukhov, A. G., & Hajela, K. (2023). Transient Receptor Potential Canonical 6 (TRPC6) Channel in the Pathogenesis of Diseases: A Jack of Many Trades. Inflammation, 1–17. https://doi.org/10.1007/s10753-023-01808-3
Scheuble, J., Rössler, O. G., Ulrich, M., & Thiel, G. (2020). Pharmacological and genetic inhibition of TRPC6-induced gene transcription. European Journal of Pharmacology, 886, 173357. https://doi.org/10.1016/j.ejphar.2020.173357
Schijvens, A. M., ter Heine, R., de Wildt, S. N., & Schreuder, M. F. (2019). Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrology (Berlin, Germany), 34(3), 389–403. https://doi.org/10.1007/s00467-018-3929-z
Schlöndorff, J. S., & Pollak, M. R. (2006). TRPC6 in glomerular health and disease: What we know and what we believe. Seminars in Cell & Developmental Biology, 17(6), 667–674. https://doi.org/10.1016/j.semcdb.2006.11.003
Schultz, A., Halabi, A., Seitz, F., Lemmens, K., Wülfrath, H. S., Lobmeyer, M. T., Retlich, S., Choi, W., & Soleymanlou, N. (2025). Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment. Expert Opinion on Investigational Drugs, 34(5), 415–423. https://doi.org/10.1080/13543784.2025.2510673
Shakeel, S., Rashid, R., Jafry, N. H., & Mubarak, M. (2024). Adult minimal change disease: Clinicopathologic characteristics, treatment response and outcome at a single center in Pakistan. World Journal of Nephrology, 13(4), 99643. https://doi.org/10.5527/wjn.v13.i4.99643
Sim, J. J., Batech, M., Hever, A., Harrison, T. N., Avelar, T., Kanter, M. H., & Jacobsen, S. J. (2016). Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. American Journal of Kidney Diseases, 68(4), 533–544. https://doi.org/10.1053/j.ajkd.2016.03.416
Takei, T., Itabashi, M., Moriyama, T., Kojima, C., Shiohira, S., Shimizu, A., Tsuruta, Y., Ochi, A., Amemiya, N., Mochizuki, T., Uchida, K., Tsuchiya, K., & Nitta, K. (2013). Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 28(5), 1225–1232. https://doi.org/10.1093/ndt/gfs515
Trachtman, H., Kretzler, M., Desmond, H. E., Choi, W., Manuel, R. C., & Soleymanlou, N. (2023). TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design. Kidney International Reports, 8(12), 2822–2825. https://doi.org/10.1016/j.ekir.2023.09.026
Trachtman, H., Modi, Z. J., Ju, W., Lee, E., Chinnakotla, S., Massengill, S., Sedor, J., Mariani, L., Zhai, Y., Hao, W., Desmond, H., Eddy, S., Ramani, K., Spino, C., & Kretzler, M. (2024). Precision Medicine Proof-of-Concept Study of a TNF Inhibitor in FSGS and Treatment-Resistant Minimal Change Disease. Kidney360, 6(2), 284–295. https://doi.org/10.34067/KID.0000000635
Udupa, K. R. N., Eshwarappa, M., Gurudev, K. C., Gireesh, M. S., Reddy, R., & Yousuff, M. (2023). Clinico-biochemical Profile of Biopsy-proven Minimal Change Disease in Adults from a Tertiary Care Center in South India. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 34(3), 242–249. https://doi.org/10.4103/1319-2442.393997
Vivarelli, M., Massella, L., Ruggiero, B., & Emma, F. (2017). Minimal Change Disease. Clinical Journal of the American Society of Nephrology : CJASN, 12(2), 332–345. https://doi.org/10.2215/CJN.05000516
Watts, A. J. B., Keller, K. H., Lerner, G., Rosales, I., Collins, A. B., Sekulic, M., Waikar, S. S., Chandraker, A., Riella, L. V., Alexander, M. P., Troost, J. P., Chen, J., Fermin, D., Yee, J. L., Sampson, M. G., Beck, L. H., Henderson, J. M., Greka, A., Rennke, H. G., & Weins, A. (2022). Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. Journal of the American Society of Nephrology : JASN, 33(1), 238–252. https://doi.org/10.1681/ASN.2021060794
Wu, H. H. L., Kalra, P. A., & Chinnadurai, R. (2021). New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. Vaccines, 9(11), 1252. https://doi.org/10.3390/vaccines9111252
Wu, L., Du, X., & Lu, X. (2023). Role of telitacicept in the treatment of IgA nephropathy. European Journal of Medical Research, 28, 369. https://doi.org/10.1186/s40001-023-01320-2
Xue, C., Yang, B., Xu, J., Zhou, C., Zhang, L., Gao, X., Dai, B., Yu, S., Mao, Z., Mei, C., & Xu, C. (2020). Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: A systematic review and meta-analysis. Clinical Kidney Journal, 14(4), 1042–1054. https://doi.org/10.1093/ckj/sfaa191
Yonemura, T., Sarashina, A., Tachibana, Y., Retlich, S., & Soleymanlou, N. (2025). A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men. Expert Opinion on Investigational Drugs, 34(5), 425–433. https://doi.org/10.1080/13543784.2025.2510664
Yuan, K., Li, X., Lu, Q., Zhu, Q., Jiang, H., Wang, T., Huang, G., & Xu, A. (2019). Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases—A Review. Frontiers in Pharmacology, 10, 1469. https://doi.org/10.3389/fphar.2019.01469
Zamora, G., & Pearson-Shaver, A. L. (2025). Minimal Change Disease. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK560639/
Zhang, Y., Yang, X., Jia, L.-Y., Liu, B.-L., Zhang, S.-R., Wang, G.-Y., Wang, L.-S., & Liu, J.-P. (2018). Tripterygium glycosides for treatment of nephrotic syndrome: A systematic review and meta-analysis of randomised controlled trials. European Journal of Integrative Medicine, 20, 131–145. https://doi.org/10.1016/j.eujim.2018.05.002
Zhao, X., Hwang, D.-Y., & Kao, H.-Y. (2018). The Role of Glucocorticoid Receptors in Podocytes and Nephrotic Syndrome. Nuclear Receptor Research, 5, 101323. https://doi.org/10.11131/2018/101323
Zhou, H., Tian, X., Tufro, A., Moeckel, G., Ishibe, S., & Goodwin, J. (2017). Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury. Scientific Reports, 7, 9833. https://doi.org/10.1038/s41598-017-10490-z
Views:
41
Downloads:
14
Copyright (c) 2025 Cezary Lubas, Joanna Kłosowska, Piotr Świerczek, Małgorzata Zach, Karolina Błądzińska, Maciej Błądziński, Kacper Szeląg, Antoni Kujawski, Paula Folta, Anna Opalińska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
